Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (82)

2024

  1. Calbindin and Girk2/Aldh1a1 define resilient vs vulnerable dopaminergic neurons in a primate Parkinson’s disease model

    npj Parkinson's Disease, Vol. 10, Núm. 1

  2. Characterization of brain transduction capability of a BBB-penetrant AAV vector in mice, rats and macaques reveals differences in expression profiles

    Gene Therapy, Vol. 31, Núm. 9-10, pp. 455-466

  3. Development and characterization of a non-human primate model of disseminated synucleinopathy

    Frontiers in Neuroanatomy, Vol. 18

  4. Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

    Movement Disorders Clinical Practice, Vol. 11, Núm. 7, pp. 830-849

  5. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

  6. The cellular prion protein does not affect tau seeding and spreading of sarkosyl-insoluble fractions from Alzheimer’s disease

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease

    Parkinsonism and Related Disorders, Vol. 110

  2. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

    Brain, Behavior, and Immunity, Vol. 108, pp. 255-268

  3. Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

    Neurobiology of Disease, Vol. 188

  4. Engineering U1-Based Tetracycline-Inducible Riboswitches to Control Gene Expression in Mammals

    ACS Nano, Vol. 17, Núm. 23, pp. 23331-23346

  5. Loss of the matrix metalloproteinase-10 causes premature features of aging in satellite cells

    Frontiers in Cell and Developmental Biology, Vol. 11

  6. Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates

    Brain : a journal of neurology, Vol. 146, Núm. 12, pp. 5000-5014

  7. Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome

    Journal of Molecular Medicine, Vol. 101, Núm. 12, pp. 1587-1601

2022

  1. Adeno-Associated Viral Vectors as Versatile Tools for Neurological Disorders: Focus on Delivery Routes and Therapeutic Perspectives

    Biomedicines, Vol. 10, Núm. 4

  2. Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment

    Life, Vol. 12, Núm. 11

  3. Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria

    Science Translational Medicine, Vol. 14, Núm. 627

2021

  1. Adeno-associated viral vectors as versatile tools for parkinson’s research, both for disease modeling purposes and for therapeutic uses

    International Journal of Molecular Sciences, Vol. 22, Núm. 12

  2. An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria

    Redox Biology, Vol. 46

  3. Armcx3 mediates susceptibility to hepatic tumorigenesis promoted by dietary lipotoxicity

    Cancers, Vol. 13, Núm. 5, pp. 1-22

  4. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

    Acta Neuropathologica Communications, Vol. 9, Núm. 1